问卷筛选试验在评估澳大利亚悉尼化脓性汗腺炎患病率中的诊断准确性。

IF 2.7 3区 医学 Q2 DERMATOLOGY
Dermatology Pub Date : 2025-07-07 DOI:10.1159/000540455
James Pham, Akshay Flora, Emily Kay Kozera, Cecilia E Medianfar, Dorra Bouazzi, Robin Christensen, Gregor B E Jemec, John W Frew
{"title":"问卷筛选试验在评估澳大利亚悉尼化脓性汗腺炎患病率中的诊断准确性。","authors":"James Pham, Akshay Flora, Emily Kay Kozera, Cecilia E Medianfar, Dorra Bouazzi, Robin Christensen, Gregor B E Jemec, John W Frew","doi":"10.1159/000540455","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant patient burden and impact on quality of life. Australia has a population of over 25 million people, with an estimated 29% of people born overseas. Previous studies have estimated the prevalence of HS in Australia to be approximately 0.67%, but methodological issues limit the accuracy of this estimate. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to objectively quantify the prevalence of HS in Australia.</p><p><strong>Methods: </strong>The methodology followed the previously published GHiSA methodology. A validated questionnaire was used to identify patients likely to have a diagnosis of HS. Screen-positive patients as well as a selection of screen-negative patients underwent clinical examination by a single physician experienced in the identification, diagnosis and management of HS to further validate the sensitivity and specificity of the questionnaire.</p><p><strong>Results: </strong>A total of 1,657 eligible healthy accompanying adults were approached, of whom 1,002 consented for inclusion in the study (60.5%). A total of 9 were survey screen-positive for HS, representing a prevalence of 0.9% (95% CI: 0.5%-1.7%).</p><p><strong>Conclusions: </strong>This single tertiary referral center study identified an HS prevalence of 0.9% in Australia. The methods address the deficiencies in other methodologies and provide insight into the prevalence of HS globally as part of the GHiSA initiative.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-5"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233957/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diagnostic Accuracy of a Questionnaire Screening Test in Assessing the Prevalence of Hidradenitis Suppurativa in Sydney, Australia.\",\"authors\":\"James Pham, Akshay Flora, Emily Kay Kozera, Cecilia E Medianfar, Dorra Bouazzi, Robin Christensen, Gregor B E Jemec, John W Frew\",\"doi\":\"10.1159/000540455\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant patient burden and impact on quality of life. Australia has a population of over 25 million people, with an estimated 29% of people born overseas. Previous studies have estimated the prevalence of HS in Australia to be approximately 0.67%, but methodological issues limit the accuracy of this estimate. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to objectively quantify the prevalence of HS in Australia.</p><p><strong>Methods: </strong>The methodology followed the previously published GHiSA methodology. A validated questionnaire was used to identify patients likely to have a diagnosis of HS. Screen-positive patients as well as a selection of screen-negative patients underwent clinical examination by a single physician experienced in the identification, diagnosis and management of HS to further validate the sensitivity and specificity of the questionnaire.</p><p><strong>Results: </strong>A total of 1,657 eligible healthy accompanying adults were approached, of whom 1,002 consented for inclusion in the study (60.5%). A total of 9 were survey screen-positive for HS, representing a prevalence of 0.9% (95% CI: 0.5%-1.7%).</p><p><strong>Conclusions: </strong>This single tertiary referral center study identified an HS prevalence of 0.9% in Australia. The methods address the deficiencies in other methodologies and provide insight into the prevalence of HS globally as part of the GHiSA initiative.</p>\",\"PeriodicalId\":11185,\"journal\":{\"name\":\"Dermatology\",\"volume\":\" \",\"pages\":\"1-5\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233957/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000540455\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540455","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

摘要化脓性汗腺炎(HS)是一种慢性炎症性皮肤病,患者负担重,影响生活质量。澳大利亚人口超过2500万,其中29%的人出生在海外。先前的研究估计澳大利亚的HS患病率约为0.67%,但方法问题限制了这一估计的准确性。本研究是全球化脓性汗腺炎地图集(GHiSA)倡议的一部分,旨在客观量化HS在澳大利亚的患病率。方法:方法遵循先前发表的GHiSA方法。一份有效的问卷被用来确定可能被诊断为HS的患者。筛检阳性患者和筛检阴性患者均由一名具有HS识别、诊断和管理经验的医生进行临床检查,进一步验证问卷的敏感性和特异性。结果:共接触了1,657名符合条件的健康陪同成人,其中1,002人同意纳入研究(60.5%)。共有9例HS筛查阳性,患病率为0.9% (95% CI: 0.5%-1.7%)。结论:这个单一的三级转诊中心研究确定了澳大利亚的HS患病率为0.9%。这些方法解决了其他方法的不足,并作为全球卫生信息安全倡议的一部分,提供了对HS全球流行情况的深入了解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Diagnostic Accuracy of a Questionnaire Screening Test in Assessing the Prevalence of Hidradenitis Suppurativa in Sydney, Australia.

Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant patient burden and impact on quality of life. Australia has a population of over 25 million people, with an estimated 29% of people born overseas. Previous studies have estimated the prevalence of HS in Australia to be approximately 0.67%, but methodological issues limit the accuracy of this estimate. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to objectively quantify the prevalence of HS in Australia.

Methods: The methodology followed the previously published GHiSA methodology. A validated questionnaire was used to identify patients likely to have a diagnosis of HS. Screen-positive patients as well as a selection of screen-negative patients underwent clinical examination by a single physician experienced in the identification, diagnosis and management of HS to further validate the sensitivity and specificity of the questionnaire.

Results: A total of 1,657 eligible healthy accompanying adults were approached, of whom 1,002 consented for inclusion in the study (60.5%). A total of 9 were survey screen-positive for HS, representing a prevalence of 0.9% (95% CI: 0.5%-1.7%).

Conclusions: This single tertiary referral center study identified an HS prevalence of 0.9% in Australia. The methods address the deficiencies in other methodologies and provide insight into the prevalence of HS globally as part of the GHiSA initiative.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Dermatology
Dermatology 医学-皮肤病学
CiteScore
6.40
自引率
2.90%
发文量
71
审稿时长
1 months
期刊介绍: Published since 1893, ''Dermatology'' provides a worldwide survey of clinical and investigative dermatology. Original papers report clinical and laboratory findings. In order to inform readers of the implications of recent research, editorials and reviews prepared by invited, internationally recognized scientists are regularly featured. In addition to original papers, the journal publishes rapid communications, short communications, and letters to ''Dermatology''. ''Dermatology'' answers the complete information needs of practitioners concerned with progress in research related to skin, clinical dermatology and therapy. The journal enjoys a high scientific reputation with a continually increasing impact factor and an equally high circulation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信